Leupin Nicolas's Form 4 filing

NovoCure Ltd (NVCR) · filed Mar 3, 2025

Accession no.: 0001562180-25-001836
Filed: Mar 3, 2025
Trade date: Feb 27, 2025
Filing delay: 4 days
Rule 10b5-1 plan: Not checked

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market sales total $19.8K. It was filed 4 days after the trade.

This filing was later replaced by the amendment 0001562180-25-001913 (Mar 3, 2025). Trade tables on this site use the amended version.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Leupin NicolasCIK 0002007766	Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Feb 27, 2025	Ordinary Shares	SSaleDisposed	−830	$19.92^F1	−$16,533.6	50,294	Direct
Feb 27, 2025	Ordinary Shares	SSaleDisposed	−161	$20.55^F2	−$3,308.55	50,133	Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

On February 27, 2025, the reporting person sold 830 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

On February 27, 2025, the reporting person sold 161 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)